Inhibrx Biosciences, Inc. Common Stock

Day range

$87.78 – $94.46

Open

$93.80

Prev close

$93.38

Volume

141.56K

Market cap

$1.37B

Shares out

14.72M

P/E

—

P/S

—

P/B

-25.94

P/FCF

—

ROE

260.8%

ROA

-89.6%

Debt/Equity

-3.33

Div yield

0.00%

As of Oct 23, 2026

• Investor presentationSep 28, 2026

  On September 28, 2026, Inhibrx Biosciences, Inc. posted an updated copy of its corporate presentation to the "Investors" tab of its website at www.inhibrx.com. The Company from time to time presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business.

• Investor presentationSep 8, 2026

  On September 8, 2026, Inhibrx posted an updated copy of its corporate presentation to the "Investors" tab of its website at www.inhibrx.com. A copy of this corporate presentation is filed as Exhibit 99.2...

• Warrant or conversionJul 16, 2026

  In connection with the funding of the Term C Loan, the Company issued to the Lenders warrants (the "Term C Warrants") to purchase 21,457 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), at an exercise price of $93.21 per share. Upon the funding of the Term D Loan, the Company is required to issue to the Lenders additional warrants (the "Term D Warrants" and together with the Term C Warrants, the "Warrants") to purchase such number of shares of the Common Stock to be equal to 2.0% of such additional funding divided by a price per share.

• Regulatory decisionJun 15, 2026

  the U.S. Food and Drug Administration (the "FDA") has accepted for filing its Biologics License Application (the "BLA") seeking approval of ozekibart (INBRX-109) for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. The FDA has not identified any filing review issues at this time and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027.

• Strategic initiativeMay 11, 2026

  Based on these promising early results, the Company also aims to evaluate INBRX-106 across broader indications to potentially improve the efficacy of checkpoint inhibitors. This strategy includes initiating a study in the perioperative setting in non-small cell lung cancer (NSCLC) later this quarter. The Company is beginning to plan for expansion into the front-line metastatic NSCLC setting, with studies expected to begin in 2027.

Days to cover

11.8

Short interest

3.43M

Avg volume

290.36K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
  positiveGlobeNewswire Inc.· Sep 1, 2026
• Inhibrx Reports First Quarter 2026 Financial Results
  neutralBenzinga· May 14, 2026
• Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
  positiveBenzinga· Apr 22, 2026
• Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?
  positiveBenzinga· Oct 24, 2025
• Why Are Inhibrx Biosciences Shares Soaring 76% After Hours?
  positiveBenzinga· Oct 24, 2025